Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Nicolini, FE; Kim, D-W; Ceglarek, B; Turkina, A; Alimena, G; Al-Ali, HK; Shen, Z; Jootar, S; Smith, G; De Souza, CA; Dorlhiac-Llacer, PE; Rizzieri, DA; Szczudlo, T; Berton, M; Wang, J; Bieri, C; le Coutre, PD

Published Date

  • November 20, 2009

Published In

Volume / Issue

  • 114 / 22

Start / End Page

  • 866 - 867

Published By


  • 2

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 51st Annual Meeting of the American-Society-of-Hematology

Conference Location

  • New Orleans, LA

Conference Start Date

  • December 5, 2009

Conference End Date

  • December 8, 2009